Welcome to our dedicated page for BioNxt Solutions news (Ticker: BNXTF), a resource for investors and traders seeking the latest updates and insights on BioNxt Solutions stock.
BioNxt Solutions Inc. reports developments in bioscience and advanced drug delivery systems, with recurring updates on sublingual oral thin films, transdermal skin patches, oral enteric-coated tablets, diagnostic screening systems and active pharmaceutical ingredient development. Its lead program, BNT23001, is a proprietary sublingual cladribine oral thin film designed for relapsing forms of multiple sclerosis and other autoimmune neurodegenerative diseases.
Company news also covers patent protection for its oral thin-film technology, GMP manufacturing of clinical-grade cladribine film through a European CDMO, semaglutide as an initial GLP-1 oral thin-film application, commercialization planning, and capital-structure actions such as shares issued to settle debt.
BioNxt Solutions has signed an agreement to conduct a comparative drug absorption study for its transdermal Rotigotine patch aimed at treating Parkinson's disease. Scheduled for early Q2 2023, the study will assess bioavailability, skin adhesion, and skin tolerance against a leading brand. BioNxt is also ramping up the manufacture of clinical samples and developing in-house commercial manufacturing capabilities at its German facility. The Parkinson's disease therapeutic market is projected to grow, with Rotigotine patch sales expected to exceed $766 million by 2030. The company aims to leverage its proprietary TDS technology for future drug development.